. Gold-guidelines, Guide to COPD diagnostic, managment and prevention, 2018.

D. Adeloye, S. Chua, C. Lee, C. Basquill, A. Papana et al., Global and regional estimates of COPD prevalence: Systematic review and meta-analysis, J Glob Health, vol.5, issue.2, p.20415, 2015.

, Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. The Lancet, janv, vol.10, issue.9963, pp.117-71, 2015.

, Bronchite chronique : prévalence et impact sur la vie quotidienne, 2002.

T. Perez, H. Mal, B. Aguilaniu, P. Brillet, A. Chaouat et al., BPCO et inflammation : mise au point d'un groupe d'experts. Les phénotypes en lien avec l'inflammation, Rev Mal Respir. févr, vol.28, issue.2, pp.192-215, 2011.

T. Chinet, J. Dumoulin, I. Honore, J. Braun, L. Couderc et al., Place des corticostéroïdes inhalés dans la BPCO, Rev Mal Respir. déc, vol.33, issue.10, pp.877-91, 2016.

J. Vestbo, S. S. Hurd, A. G. Agustí, P. W. Jones, C. Vogelmeier et al., Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary, Am J Respir Crit Care Med. 15 févr, vol.187, issue.4, pp.347-65, 2013.

J. C. Hogg, F. Chu, S. Utokaparch, R. Woods, W. M. Elliott et al., The nature of smallairway obstruction in chronic obstructive pulmonary disease, N Engl J Med. 24 juin, vol.350, issue.26, pp.2645-53, 2004.

R. A. O'donnell, C. Peebles, J. A. Ward, A. Daraker, G. Angco et al., Relationship between peripheral airway dysfunction, airway obstruction, and neutrophilic inflammation in COPD, Thorax. oct, vol.59, issue.10, pp.837-879, 2004.

D. St?nescu, A. Sanna, C. Veriter, S. Kostianev, P. G. Calcagni et al., Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils, Thorax. mars, vol.51, issue.3, pp.267-71, 1996.

M. Saetta, D. Stefano, A. Turato, G. Facchini, F. M. Corbino et al., CD8+ Tlymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease, Am J Respir Crit Care Med. mars, vol.157, issue.3, pp.822-828, 1998.

A. Papi, M. Romagnoli, S. Baraldo, F. Braccioni, I. Guzzinati et al., Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease, Am J Respir Crit Care Med. nov, vol.162, issue.5, pp.1773-1780, 2000.

R. E. Louis, D. Cataldo, M. G. Buckley, J. Sele, M. Henket et al., Evidence of mast-cell activation in a subset of patients with eosinophilic chronic obstructive pulmonary disease, Eur Respir J. 1 août, vol.20, issue.2, pp.325-356, 2002.

C. E. Brightling, W. Monteiro, R. Ward, D. Parker, M. D. Morgan et al., Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial, Lancet Lond Engl, vol.356, issue.9240, pp.1480-1485, 2000.

J. B. Snoeck-stroband, T. S. Lapperre, M. Gosman, H. M. Boezen, W. Timens et al., Chronic bronchitis sub-phenotype within COPD: inflammation in sputum and biopsies, Eur Respir J. 1 janv, vol.31, issue.1, pp.70-77, 2008.

T. C. O'shaughnessy, T. W. Ansari, N. C. Barnes, and P. K. Jeffery, Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes with FEV1, Am J Respir Crit Care Med. mars, vol.155, issue.3, pp.852-859, 1997.

A. M. Vignola, F. Paganin, L. Capieu, N. Scichilone, M. Bellia et al., Airway remodelling assessed by sputum and high-resolution computed tomography in asthma and COPD, Eur Respir J. 1 déc, vol.24, issue.6, pp.910-917, 2004.

D. Cataldo, C. Munaut, A. Noël, F. Frankenne, P. Bartsch et al., MMP-2-and MMP-9-linked gelatinolytic activity in the sputum from patients with asthma and chronic obstructive pulmonary disease. Int Arch Allergy Immunol, vol.123, pp.259-67, 2000.

, European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency, Am J Respir Crit Care Med, vol.168, issue.7, pp.818-900, 2003.

M. I. Zervou, E. G. Tzortzaki, D. Makris, M. Gaga, E. Zervas et al., Differences in microsatellite DNA level between asthma and chronic obstructive pulmonary disease, Eur Respir J. 1 sept, vol.28, issue.3, pp.472-480, 2006.

S. S. Salvi and P. J. Barnes, Chronic obstructive pulmonary disease in non-smokers. The Lancet, août, vol.29, issue.9691, pp.733-776, 2009.

A. D. Lopez, C. D. Mathers, M. Ezzati, D. T. Jamison, and C. Murray, Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data, Lancet Lond Engl. 27 mai, vol.367, issue.9524, pp.1747-57, 2006.

J. Balmes, M. Becklake, P. Blanc, P. Henneberger, K. Kreiss et al., American Thoracic Society Statement: Occupational contribution to the burden of airway disease, Am J Respir Crit Care Med. 1 mars, vol.167, issue.5, pp.787-97, 2003.

B. Ulvestad, B. Bakke, E. W. Kongerud, J. Lund, and M. , Cumulative exposure to dust causes accelerated decline in lung function in tunnel workers, Occup Environ Med, vol.58, issue.10, pp.663-672, 2001.

A. S. Fairbairn and D. D. Reid, Air Pollution and Other Local Factors in Respiratory Disease, Br J Prev Soc Med. avr, vol.12, issue.2, pp.94-103, 1958.

R. I. Ehrlich, N. White, R. Norman, R. Laubscher, K. Steyn et al., Predictors of chronic bronchitis in South African adults, Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis. mars, vol.8, issue.3, pp.369-76, 2004.

A. Agusti, P. M. Calverley, B. Celli, H. O. Coxson, L. D. Edwards et al., Characterisation of COPD heterogeneity in the ECLIPSE cohort, Respir Res. 10 sept, vol.11, issue.1, p.122, 2010.

P. Calverley, K. Tetzlaff, C. Vogelmeier, L. M. Fabbri, H. Magnussen et al., Frequent Exacerbations, and Steroid Response in Chronic Obstructive Pulmonary Disease, Am J Respir Crit Care Med. 17 mars, vol.196, issue.9, pp.1219-1240, 2017.

S. H. Siddiqui, A. Guasconi, J. Vestbo, P. Jones, A. Agusti et al., Blood Eosinophils: A Biomarker of Response to Extrafine Beclomethasone/Formoterol in Chronic Obstructive Pulmonary Disease, Am J Respir Crit Care Med. 15 août, vol.192, issue.4, pp.523-528, 2015.

G. G. Brusselle, T. Maes, and K. R. Bracke, Eosinophils in the spotlight: Eosinophilic airway inflammation in nonallergic asthma, Nat Med. août, vol.19, issue.8, pp.977-986, 2013.

J. Yayan and K. Rasche, Asthma and COPD: Similarities and Differences in the Pathophysiology, Diagnosis and Therapy, Adv Exp Med Biol, vol.910, pp.31-39, 2016.

. Gina-guidelines, Global strategy for Asthma management and Prevention, 2017.

S. Bujarski, A. D. Parulekar, A. Sharafkhaneh, and N. A. Hanania, The asthma COPD overlap syndrome (ACOS), Curr Allergy Asthma Rep. mars, vol.15, issue.3, p.509, 2015.

D. D. Sin, M. Miravitlles, D. M. Mannino, J. B. Soriano, D. Price et al., What is asthma-COPD overlap syndrome? Towards a consensus definition from a round table discussion, Eur Respir J, vol.48, issue.3, pp.664-73, 2016.

S. E. Marsh, J. Travers, M. Weatherall, M. V. Williams, S. Aldington et al., Proportional classifications of COPD phenotypes, Thorax. sept, vol.63, issue.9, pp.761-768, 2008.

J. B. Soriano, K. J. Davis, B. Coleman, G. Visick, D. Mannino et al., The proportional Venn diagram of obstructive lung disease: two approximations from the United States and the United Kingdom, Chest. août, vol.124, issue.2, pp.474-81, 2003.

C. Rubio, M. Casamor, R. Miravitlles, and M. , Identification and distribution of COPD phenotypes in clinical practice according to Spanish COPD Guidelines: the FENEPOC study, Int J Chron Obstruct Pulmon Dis. 9 août, vol.12, pp.2373-83, 2017.

A. Menezes, M. Montes-de-oca, R. Pérez-padilla, G. Nadeau, F. C. Wehrmeister et al., Increased risk of exacerbation and hospitalization in subjects with an overlap phenotype: COPD-asthma, Chest. févr, vol.145, issue.2, pp.297-304, 2014.

C. M. Blanchette, B. Gutierrez, C. Ory, E. Chang, and M. Akazawa, Economic burden in direct costs of concomitant chronic obstructive pulmonary disease and asthma in a Medicare Advantage population, J Manag Care Pharm JMCP. mars, vol.14, issue.2, pp.176-85, 2008.

J. Fingleton, K. Huang, M. Weatherall, Y. Guo, S. Ivanov et al., Phenotypes of symptomatic airways disease in China and New Zealand, Eur Respir J. déc, vol.50, issue.6, 2017.

Y. Kitaguchi, Y. Komatsu, K. Fujimoto, M. Hanaoka, and K. Kubo, Sputum eosinophilia can predict responsiveness to inhaled corticosteroid treatment in patients with overlap syndrome of COPD and asthma, Int J Chron Obstruct Pulmon Dis, vol.7, pp.283-292, 2012.

M. Hikichi, S. Hashimoto, and Y. Gon, Asthma and COPD overlap pathophysiology of ACO, Allergol Int Off J Jpn Soc Allergol. avr, vol.67, issue.2, pp.179-86, 2018.

B. G. Cosio, J. B. Soriano, J. L. López-campos, M. Calle-rubio, J. J. Soler-cataluna et al., Defining the Asthma-COPD Overlap Syndrome in a COPD Cohort, Chest. janv, vol.149, issue.1, pp.45-52, 2016.

Y. Kitaguchi, K. Fujimoto, K. Kubo, and T. Honda, Characteristics of COPD phenotypes classified according to the findings of HRCT, Respir Med, vol.100, issue.10, pp.1742-52, 2006.

H. Andersén, P. Lampela, A. Nevanlinna, O. Säynäjäkangas, and T. Keistinen, High hospital burden in overlap syndrome of asthma and COPD, Clin Respir J. oct, vol.7, issue.4, pp.342-348, 2013.

F. T. Shaya, D. Dongyi, M. O. Akazawa, C. M. Blanchette, J. Wang et al., Burden of concomitant asthma and COPD in a Medicaid population, Chest. juill, vol.134, issue.1, pp.14-23, 2008.

R. Golpe, M. Suárez-valor, I. Martín-robles, P. Sanjuán-lópez, E. Cano-jiménez et al., Mortality in COPD patients according to clinical phenotypes, Int J Chron Obstruct Pulmon Dis, vol.13, pp.1433-1442, 2018.

I. D. Pavord, P. Chanez, G. J. Criner, H. Kerstjens, S. Korn et al., Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease, N Engl J Med, vol.26, issue.17, pp.1613-1642, 2017.

T. S. Tat and A. Cilli, Omalizumab treatment in asthma-COPD overlap syndrome, J Asthma Off J Assoc Care Asthma. déc, vol.53, issue.10, pp.1048-50, 2016.

V. Garelli, N. Petitpierre, and L. P. Nicod, Le syndrome de chevauchement asthme-BPCO, Rev Med Suisse, vol.11, pp.2145-2150, 2015.

A. Mendy, E. Forno, T. Niyonsenga, R. Carnahan, and J. Gasana, Prevalence and Features of Asthma-COPD Overlap in the, Clin Respir J, vol.5, 2007.

B. Alcázar-navarrete, J. A. Trigueros, J. A. Riesco, A. Campuzano, and J. Pérez, Geographic variations of the prevalence and distribution of COPD phenotypes in Spain: “the ESPIRAL-ES study&rdquo, International Journal of Chronic Obstructive Pulmonary Disease, 2018.

L. Ekerljung, R. Mincheva, S. Hagstad, A. Bjerg, G. Telg et al., Prevalence, clinical characteristics and morbidity of the Asthma-COPD overlap in a general population sample, J Asthma Off J Assoc Care Asthma. mai, vol.55, issue.5, pp.461-470, 2018.

D. Caillaud, P. Chanez, R. Escamilla, P. Burgel, I. Court-fortune et al., Asthma-COPD overlap syndrome (ACOS) vs « pure » COPD: a distinct phenotype?, Allergy. janv, vol.72, issue.1, pp.137-182, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01813294

L. Pérez-de-llano, B. G. Cosío, M. Miravitlles, V. Plaza, . Chacos et al., Accuracy of a New Algorithm to Identify Asthma-COPD Overlap (ACO) Patients in a Cohort of Patients with Chronic Obstructive Airway Disease, Arch Bronconeumol. avr, vol.54, issue.4, pp.198-204, 2018.

A. Alshabanat, Z. Zafari, O. Albanyan, M. Dairi, and J. M. Fitzgerald, Asthma and COPD Overlap Syndrome (ACOS): A Systematic Review and Meta Analysis, PLOS ONE. 3 sept, vol.10, issue.9, p.136065, 2015.

P. Nair, M. Pizzichini, M. Kjarsgaard, M. D. Inman, A. Efthimiadis et al., Mepolizumab for prednisone-dependent asthma with sputum eosinophilia, N Engl J Med. 5 mars, vol.360, issue.10, pp.985-93, 2009.

G. A. Westerhof, D. A. Korevaar, M. Amelink, S. B. De-nijs, J. C. De-groot et al., Biomarkers to identify sputum eosinophilia in different adult asthma phenotypes, Eur Respir J. sept, vol.46, issue.3, pp.688-96, 2015.

B. R. Celli, C. G. Cote, J. M. Marin, C. Casanova, M. Montes-de-oca et al., The BodyMass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity Index in Chronic Obstructive Pulmonary Disease, N Engl J Med. 4 mars, vol.350, issue.10, pp.1005-1017, 2004.

H. Gharsalli, O. Neffati, S. Aouadi, A. Bayoudh, S. Mokkadem et al., Caractéristiques des patients BPCO exacerbateurs fréquents, Rev Mal Respir. janv, vol.32, p.83, 2015.

F. Oussedik, R. Khelafi, and F. Skander, Impact des exacerbations de BPCO sur la mortalité, Rev Mal Respir. janv, vol.33, p.19, 2016.

, Etude de la prévalence et des caractéristiques des ACOS parmi la cohorte de BPCO du CHU d'Amiens Introduction : Le syndrome de chevauchement asthme-BPCO (ACOS) pourrait être un phénotype de BPCO. L'objectif était d'estimer la prévalence des patients répondant aux critères d'ACOS

. Méthodes, Une étude rétrospective a été menée entre mai 2017 et mai 2018 sur la cohorte de BPCO du CHU d'Amiens. Deux définitions étaient utilisées en l'absence de définition consensuelle : un score diagnostique basé sur les critères du GINA

. Résultats, 6%) patients présentaient un ACOS suivant respectivement la définition du score diagnostique et celle du consensus, prévalence modifiée à 43 (32,1%) et 16 (11,2%) sur 134 patients BPCO après exclusion des patients emphysémateux et des patients n'ayant pas un trouble ventilatoire confirmé. Les patients ACOS étaient moins graves (VEMS à 67,9% vs 58.6%, p=0.024, BODE index 0.8 vs 1.79, p<0.001) mais aussi exacerbateurs fréquents (p=0.47) que les patients BPCO. Les patients ACOS étaient plus souvent asthmatiques (p<0.001) et avaient plus souvent des symptômes précoces (p<0.001), des antécédents personnels (p=0.021) ou familiaux d'allergie (p=0.023), une hyperéosinophilie (p=0.017) ou des IgE totales élevées (p=0.008)

, à 32,1% répondent aux critères d'ACOS. Il s'agit de patients moins sévères mais tout aussi exacerbateurs fréquents que les BPCO, plus souvent associés à une hyperéosinophilie et à des antécédents personnels ou familiaux d'asthme ou d'allergie. La réversibilité des EFR semble être un critère ni nécessaire ni suffisant, Conclusion : Parmi les patients suivis pour une BPCO au CHU d'Amiens, vol.11

, Mots clefs : BPCO ; asthme ; ACOS ; trouble ventilatoire obstructif

A. and -. Syndrome, Prevalence and characteristics of ACOS among COPD cohort in Amiens University Hospital. Introduction: Asthma-and-COPD overlap syndrome (ACOS) could be a COPD phenotype. We aimed to determine prevalence and characteristics of patients who could be, ACOS in the Amiens University Hospital COPD cohort

, Two definitions were used because of the lack of an official definition: a diagnostic score based on GINA standards, and one diagnostics proposed by an expert consensus. Results: Among all COPD patients, 49 (13,3%) et 17 (4.6%) were ACOS respectively following the score definition and the consensus definition, and 43 (32,1%) and 16 (11,2%) among 134 COPD patients after removing emphysematous patients and non-confirmed obstructive trouble. ACOS people were less serious (FEV1: 67,9% vs 58.6%, p=0.024, BODE index 0.8 vs 1.79, p<0.001) but as frequents exacerbators as non-ACOS COPD patients (p=0.47). ACOS patients had more often asthma (p<0.001), early symptoms (p<0.001), familial (p=0.023) or personal (p=0.021) allergy, hypereosinophilia (p=0.017) or high total IgE (p=0.008). No difference was seen in spirometrics, Methods: We conducted a retrospective study from may 2017 to may 2018 among the Amiens University Hospital COPD cohort